EA! -- Patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure (such as balloon angioplasty) and received a lower dose of the anticoagulant heparin during the procedure did not have a reduced rate of major bleeding and vascular access site complications, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.
